Glycomics

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, QC, GPU, Utrecht University, Pharmacy, IRT, Drug discovery, Radboud University Nijmegen, Cell biology, Biomarker, Molecular genetics, Bruker, University, Ultra, University of Michigan, Proteomics, Peptide, Infection, Pulse, Neoplasm, Glycomics, Lunenfeld-Tanenbaum Research Institute, TIMS, Multimedia, Medical director, BRKR, Pathology, Medical device

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Key Points: 
  • At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
  • The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker.
  • Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling.
  • Our software suite supports the analysis of PASEF data, and we are delighted that Bruker now offers it with timsTOF instruments.

Glycomics Market Size, Share & Trends Analysis Report 2023: Enzymes, Kits, Reagents, Instruments, Drug Discovery & Development, Diagnostics - Global Market to Reach $4.92 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Pharmaceutical, Health, Biometrics, Medicine, Research, National Cancer Institute, HPLC, Informatics, Enzyme, CE, Capillary electrophoresis, Drug discovery, Mass spectrometry, Glycomics, Biomarker, Pharmaceutical industry, Diagnosis

Growing research and development in the glycomics space, owing to its crucial role in various biological processes, is projected to drive the global market.

Key Points: 
  • Growing research and development in the glycomics space, owing to its crucial role in various biological processes, is projected to drive the global market.
  • Moreover, the increasing demand for personalized medicine has further supported industry growth as glycomics plays a significant role in developing glycan-based diagnostic solutions.
  • Recently glycomics have shown promise in identifying disease-specific glycan biomarkers for early detection and diagnosis of various health conditions.
  • For instance, in November 2021 GlycoPath Inc. launched its glycan imaging kit for glycoproteomic analysis of clinical and research samples.

Global Glycomics Market Report 2023: Sector to Reach $3.46 Billion by 2028 at a 15.6% CAGR - ResearchAndMarkets.com

Retrieved on: 
Friday, April 14, 2023
Health, Biotechnology, Acceleration, Molecular biology, Enzyme, Glycomics, Therapy, Prevalence, Diabetes, Mass spectrometry, COVID-19, Cardiovascular disease, Cancer, DSM-IV codes, Research, Glycobiology, Person, Organization, DART, Acquisition, Investment, Developed country, Application, Medicine, Growth, Drug discovery, Protein engineering, Conditional sentence, R, IonSense, HPLC, Reagent, D, Video game, Pharmaceutical industry, Fine chemical, Medical imaging

The global glycomics market was valued at US$1.46 billion in 2022 and is expected to grow to US$3.46 billion in 2028.

Key Points: 
  • The global glycomics market was valued at US$1.46 billion in 2022 and is expected to grow to US$3.46 billion in 2028.
  • Hence, increased demand for medications and treatments is propelling the pharmaceutical & biotechnology companies sector in the glycomics market forward.
  • China's glycomics market dominated the Asia Pacific market due to the increasing investment, and funding by pharmaceutical companies for glycomics research.
  • The glycomics market is expanding mainly because of increased glycomics research efforts and increased R&D expenditures by pharmaceutical and biotechnology companies.

Asia Pacific Glycomic Therapeutics Market Report 2023: Featuring Biomarin Pharmaceutical, Genzyme, Bayer, Glaxosmithkline & F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Glycosaminoglycan, Cataract, Bayer, Erythropoietin, GlaxoSmithKline, COVID-19, Enzyme replacement therapy, Government, Heparin, Precision medicine, Neuraminidase, Genzyme, Glycomics, Interferon, Glycoprotein, Alzheimer's disease, Proteoglycan, Gaucher's disease, Therapy, Center for Urban and Regional Analysis, Tissue plasminogen activator, Anemia, Research, Cancer, Thrombosis, Glycosphingolipid, GPI, ERT, Pharmaceutical industry, Fine chemical, Sanofi, Selectin

The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific.

Key Points: 
  • The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific.
  • The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
  • Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.
  • ; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics market in Asia Pacific.

Outlook on the Glycomics Global Market to 2029 - Rising R&D Investment by Biotechnology Companies for Novel Drug Development Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Biotechnology, Pharmaceutical, Health, Glycomics, Enzyme, Diagnosis, Drug discovery, Government, Proteomics, Hospital, Cros, Cancer, Biotechnology, Drug development, Growth, Research, Investment, Policy, Therapy, Fine chemical

Rising R&D investment by biotechnology companies for novel drug development is a key driver for the growth of the global glycomics market.

Key Points: 
  • Rising R&D investment by biotechnology companies for novel drug development is a key driver for the growth of the global glycomics market.
  • This is attributed to the recurrent application of in discovery of novel drugs and diagnostic testing coupled with re-purchases, worldwide.
  • The biopharmaceutical & biotechnology companies segment accounted for the highest revenue in 2021 and is projected to maintain its dominance over the forecast period.
  • Rising R&D investment by public and private investors is a key factor that is expected to drive the segment growth.

Global Glycomic Therapeutics Market Forecast to 2028 - Wide Applications of Glycomics in Therapeutics Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Health, General Health, Therapy, Mode, Network, Development, Alzheimer's disease, Drug discovery, Glycomics, EPO, Patient, Thrombosis, Cancer, Developing country, Anemia, Research, Traumatic brain injury, Erythropoietin, TBI, University of Alberta, Quality of life, Cataract, COVID-19, Quantum Leap, Glycan, University, Adelaide, Merck, Discovery, Trastuzumab, Pharmaceutical industry, Vaccine

The "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action" report has been added to ResearchAndMarkets.com's offering.
  • The global glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.
  • Glycan-based therapeutics have wide applications in the pharmaceutical industry; the products are available in different structures & forms and developed as per the application.
  • The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells.

Global Glycomics/Glycobiology Market Report 2022: Glycomics Applications in Precision Medicine Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Health, Biotechnology, Glycomics, Region, Growth, Chromatography, Partnership, Biotechnology, USD, Drug discovery, Mass spectrometry, Research, Kits, Investment, Fine chemical, Carbohydrate, Array, Glycoside hydrolase, Transferase, Enzyme

The global glycomics/glycobiology market is projected to reach USD 3.7 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 15.5% during the forecast period.

Key Points: 
  • The global glycomics/glycobiology market is projected to reach USD 3.7 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 15.5% during the forecast period.
  • Based on product, the glycomics/glycobiology market is segmented into enzymes, kits, instruments, carbohydrates and reagents & chemicals.
  • In 2021, the drug discovery & development segment accounted for the largest share of the market.
  • In this region, US reports the fastest growth of the glycomics/glycobiology market.

Global Glycomics/Glycobiology Market to Reach $3.5 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Health, General Health, Growth, COVID-19, Reagent, Kits, CAGR, Glycomics, Enzyme, Pet

In the changed post COVID-19 business landscape, the global market for Glycomics / Glycobiology is estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 16.7% over the analysis period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Glycomics / Glycobiology is estimated at US$1.2 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 16.7% over the analysis period 2020-2027.
  • Enzymes, one of the segments analyzed in the report, is projected to record a 17.7% CAGR and reach US$1.6 Billion by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$604.3 Million by the year 2027 trailing a CAGR of 16.1% over the analysis period 2020 to 2027.
  • In the global Instruments segment, USA, Canada, Japan, China and Europe will drive the 15.1% CAGR estimated for this segment.

LimmaTech Enters Exclusive License and Collaboration Agreement with Griffith University to Expand its Vaccine Technology Platform

Retrieved on: 
Monday, October 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Clinical Trials, Griffith University, GSK, Disease, Risk, Griffith, Woman, Infection, Vaccine, Severe cognitive impairment, Gonorrhea, Institute, HIV, Vertically transmitted infection, Acquisition, Antibody, Infertility, Glycomics, Antigen, Engineering, Pharmaceutical industry

The company has obtained an exclusive license to a suite of vaccine technologies developed by Professors Michael Jennings and Kate Seib at Griffith Universitys Institute for Glycomics.

Key Points: 
  • The company has obtained an exclusive license to a suite of vaccine technologies developed by Professors Michael Jennings and Kate Seib at Griffith Universitys Institute for Glycomics.
  • LimmaTech will initially use the technologies as well as its in-house expertise to develop the worlds first gonorrhea vaccine.
  • Antibiotic resistance and rising rates of gonorrhoea infections worldwide demonstrate the need for a gonococcal vaccine that can protect against potentially life-threatening variants.
  • Antibodies against our antigens are functionally active in a variety of relevant assays, demonstrating promising vaccine efficacy, commented Dr. Michael Kowarik, Chief Scientific Officer of LimmaTech.

Global Glycomics Market Report 2022: Growing Research Activities in Glycomics Fueling Sector Expansion - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, Genetics, General Health, Research, Science, Biotechnology, Cystic fibrosis, Cancer, Glycomics, Government, Proteomics, Drug development, Research, Industry, SIB, Knowledge, Drug discovery, Health, CAGR, Neurodegeneration, Geography, Infection, Growth, Enzyme, Conditional sentence, Patient, Investment, University, Fine chemical, Pharmaceutical industry

The Glycomics Market is evaluated at US$1,174.889 million for the year 2022, growing at a CAGR of 8.63%, reaching the market size of US$2,096.655 million by the year 2027.

Key Points: 
  • The Glycomics Market is evaluated at US$1,174.889 million for the year 2022, growing at a CAGR of 8.63%, reaching the market size of US$2,096.655 million by the year 2027.
  • The global glycomics market is anticipated to propel at a noteworthy CAGR primarily attributable to the growing research activities in glycomics in many parts of the world.
  • Additionally, the profitable investments by pharmaceutical companies in research and development activities also play a significant role in shaping the market growth over the forecast period.
  • Some of these are:
    In April 2022, GlycoNet, a leading global in glycomics research and drug development, has declared a $1.73 million investment in 13 glycomics projects across Canada.